Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments.
Adult
Aged
Disease Progression
Drug Combinations
Folic Acid
/ therapeutic use
Humans
Hypertension
/ therapy
Male
Middle Aged
Plant Extracts
/ therapeutic use
Prostatitis
/ therapy
Quality of Life
Riboflavin
/ therapeutic use
Serenoa
Surveys and Questionnaires
Thiamine
/ therapeutic use
Treatment Outcome
Vitamin B 12
/ therapeutic use
Vitamin B 6
/ therapeutic use
Young Adult
CP/CPPS
Chronic pelvic pain syndrome
Serenoa repens
chronic prostatitis
deprox
flower pollen extract
prostatitis
vitamins.
Journal
Anti-inflammatory & anti-allergy agents in medicinal chemistry
ISSN: 1875-614X
Titre abrégé: Antiinflamm Antiallergy Agents Med Chem
Pays: United Arab Emirates
ID NLM: 101462262
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
08
2018
revised:
14
11
2018
accepted:
19
11
2018
pubmed:
30
11
2018
medline:
7
1
2020
entrez:
30
11
2018
Statut:
ppublish
Résumé
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is reported in the literature ranging from 1 to 14.2%. The aim of the present study was to assess the impact on patient's quality of life and symptoms of Flower pollen extract in association with vitamins (Deprox 500®) in comparison with Serenoa repens 320 mg (Permixon 320 mg® by Pierre Fabre) in patients with CP/CPPS. All consecutive patients, with a diagnosis of CP/CPPS, referred to our center from January to August 2016, were screened to be enrolled in this single-center, randomized, controlled trial. The main outcome measure was the evaluation of IPSS/NIHCPSI (International Prostatic Symptom Score/NIH-Chronic Prostatitis Symptom Index) score variation and the assessment of the quality of life and symptoms at the end of the therapy. The second outcome measure was the evaluation of the comorbidity role in the CP/CPPS therapy. 63 patients were analyzed; patients were randomized into two groups: 29 patients were treated with Deprox 500® 2 tablets/day for 6 weeks and 34 patients with Serenoa repens 320 mg, 1 tablet/day for 6 weeks. The mean score variation for IPSS was -12.7 ± 4.3 in the Deprox 500® group and -7.8 ± 4.7 in the Serenoa repens group (p=0.0005) while for NIH-CPSI was -17.3±3.1 in the Deprox 500® group and -13.6±4.8 in the Serenoa repens group (p=0.0016). By accounting only the symptoms part of NIH-CPSI questionnaire, the mean score variation reported was -11.5±2.5 in the Deprox 500® group and -9.02±4.0 in the Serenoa repens group (p=0.009321). Furthermore, analyzing the comorbidity subgroups, in patients with hypertension, the mean IPSS score variation was -14.3±3.2 in the Deprox 500® group and - 9.02±4.0 in the Serenoa repens group. In conclusion, in patients with CP/CPPS, Deprox 500® improves IPSS and NIH-CPSI scores up to 74.5% and 84.5% respectively. Furthermore, in patients with hypertension, the antioxidant effect of Deprox 500® reduces the mean IPSS score of 82.7%.
Identifiants
pubmed: 30488800
pii: AIAAMC-EPUB-94869
doi: 10.2174/1871523018666181128164252
pmc: PMC6751341
doi:
Substances chimiques
DEPROX 500
0
Drug Combinations
0
Plant Extracts
0
Vitamin B 6
8059-24-3
Folic Acid
935E97BOY8
saw palmetto extract
J7WWH9M8QS
Vitamin B 12
P6YC3EG204
Riboflavin
TLM2976OFR
Thiamine
X66NSO3N35
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-161Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
BJU Int. 2000 May;85(7):836-41
pubmed: 10792162
BJU Int. 2000 Sep;86(4):443-8
pubmed: 10971269
Zhonghua Nan Ke Xue. 2015 Feb;21(2):107-12
pubmed: 25796681
J Urol. 1998 Apr;159(4):1224-8
pubmed: 9507840
BMC Urol. 2015 Dec 07;15:120
pubmed: 26643109
Drugs. 2009;69(1):71-84
pubmed: 19192937
Pain. 2005 Mar;114(1-2):266-77
pubmed: 15733653
Curr Urol Rep. 2006 Jul;7(4):260-5
pubmed: 16930496
BMC Urol. 2017 Apr 21;17(1):32
pubmed: 28431537
BJU Int. 2015 Oct;116(4):509-25
pubmed: 25711488
Urology. 2006 Jan;67(1):60-3
pubmed: 16413333
BJU Int. 2012 Jun;109(12):1756-61
pubmed: 22551330
Nutrients. 2013 Sep 13;5(9):3617-33
pubmed: 24067389
Urol Int. 2016;96(4):449-58
pubmed: 26745140
Urologia. 2013 Apr 24;80 Suppl 22:5-10
pubmed: 23334883
Expert Opin Pharmacother. 2010 Jun;11(8):1255-61
pubmed: 20429665
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Molecules. 2018 May 11;23(5):
pubmed: 29751604
Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S85-90
pubmed: 18164907
Eur J Pain. 2014 Jan;18(1):76-85
pubmed: 24038589
Br J Urol. 1993 Apr;71(4):433-8
pubmed: 8499988
Int J Vitam Nutr Res. 1988;58(4):436-41
pubmed: 3072307
Eur J Pharmacol. 2009 Jun 10;612(1-3):41-7
pubmed: 19393643
BJU Int. 2008 Jan;101(1):45-51
pubmed: 17868419
JAMA. 1999 Jul 21;282(3):236-7
pubmed: 10422990
Urology. 1993 Apr;41(4):301-7
pubmed: 8470312
J Urol. 2004 Jan;171(1):279-83
pubmed: 14665894
Prostate. 2015 Dec;75(16):1857-67
pubmed: 26306400
Urol Int. 2016;97(3):330-335
pubmed: 27509202
Eur J Pharmacol. 2009 Jan 14;602(2-3):230-7
pubmed: 19073169
Exp Ther Med. 2014 Oct;8(4):1032-1038
pubmed: 25187793
Curr Urol Rep. 2002 Aug;3(4):301-6
pubmed: 12149161
Eur Urol. 2009 Sep;56(3):544-51
pubmed: 19524353
Rev Urol. 2007 Spring;9(2):63-72
pubmed: 17592539
Urol Int. 2010;84(4):400-6
pubmed: 20332612